Norway - 86 companies
       
 
       
  Medical Advisor Cardiovascular...
  Senior Director of Industrialization
  Publishing Editor/Scientific Consultant on Biological Sciences
       
       
       
     
   
 
 
 
 
 
 
 
 
 
     
 
       

       
     
 
 

   
02.07.2010 Second Phase III Study Showed Avastin-Containing Regimen Helped Women with Ovarian Cancer Live Longer Without their Disease Getting Worse
Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.  Adverse events were consistent with those observed in pivotal trials of Avastin across tumor types for approved indications.  Data from the study, known as ICON7, will be submitted for presentation at an upcoming medical meeting.
 
01.07.2010 Oxford BioMedica and VIB-K.U.Leuven Announce Collaborative Research Project Funded by The Motor Neurone Disease Association to Develop MoNuDin for Treatment of Amyotrophic Lateral Sclerosis
Oxford Biomedica (LSE:OXB), the leading UK gene therapy company, VIB, a life sciences research institute in Flanders, Belgium and the UK Motor Neurone Disease Association (MND Association) are pleased to announce the award by MND Association of a research grant to support the further preclinical evaluation of MoNuDin® for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease). The grant is for £255,000 and will fund a collaborative project between Oxford BioMedica and the research gro up of Professor Peter Carmeliet, Director of the VIB Vesalius Research Center and Professor of Medicine at K.U. Leuven.
 
01.07.2010 MorphoSys Announces Clinical Milestone from Strategic Alliance
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. Today's news represents the second HuCAL-derived antibody to achieve this stage during the course of 2010, following a clinical milestone hit as part of the alliance with Centocor in June 2010.
 
 
 
 
 
 
PhD candidate who is going to complete PhD degree requirements by October 2010
Molecular Biologist - Doctorate with 7 years...
R&D Engineer
Project and Operations Manager/Senior Scientist...
PhD seeking job in Europe
Seeking for a job in the field of Clinical Research...
President, CEO, Human Resources Manager
 Ph.D. degree in Pharmaceutical Sciences with...
 Biotechnologist with 5 years of experience in...
 Chemist with ten years of solid experience...
 Application Scientist for Protein Purification
 PhD in Bioinformatics
 Business Developer & Licensing Europe
 MSc in Biotechnology
 Research Scientist
 Ph.D., senior lecture
 MSc in Biotechnology
 Research Associate
 Ph.D., senior lecture
 
   
   
 
 

Innovation Days 2010, a Pharma & Biotech event

 

4-5 October 2010

 

Universal Medica Group is pleased to announce the Innovation Days 2010, a Pharma & Biotech event to be held in Paris, on 4th & 5th October, 2010. The aim of the Innovation Days is to bring together people from Biotech and Pharmaceutical companies, encourage innovative talent and the development of bio-industries.

 
 
   
 

                                                                

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved